Literature DB >> 22386878

Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse.

Giuseppe Danilo Norata1, Vivek Krishna Pulakazhi Venu, Elisa Callegari, Valentina Paloschi, Alberico Luigi Catapano.   

Abstract

The reduced expression (haplodeficiency) of the main brain derived neurotrophic factor receptor, namely TrkB is associated with reduced atherosclerosis, smooth muscle cells accumulation and collagen content in the lesion. These data support the concept that brain derived neurotrophic factor of vascular origin may contribute to atherosclerosis. However, to date, no experimental approach was possible to investigate this issue due to the lethality of brain derived neurotrophic factor null mice. To overcome these limitations, we generated a mouse model with a conditional deletion of brain derived neurotrophic factor in endothelial cells (Tie-2 Cre recombinase) on an atherosclerotic prone background (apolipoprotein E knock out) and investigated the effect of conditional brain derived neurotrophic factor deficiency on atherosclerosis. Despite brain derived neurotrophic factor reduction in the vascular wall, mice with conditional deletion of brain derived neurotrophic factor did not develop larger atherosclerotic lesion compared to controls. Smooth muscle cell content as well as the distribution of total and fibrillar collagen was similar in the atherosclerotic lesions from mice with brain derived neurotrophic factor conditional deficiency compared to controls. Finally an extended gene expression analysis failed to identify pro-atherogenic gene expression patterns among the animal with brain derived neurotrophic factor deficiency. In spite of the reduced brain derived neurotrophic factor expression, similar atherosclerosis development was observed in the brain derived neurotrophic factor conditional deficient mouse compared to controls. These pieces of evidence indicate that endothelial derived-brain derived neurotrophic factor is not a pro-atherogenic factor and would rather suggest to investigate the role of other TrkB activators on atherosclerosis.
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386878     DOI: 10.1016/j.bbadis.2012.02.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice.

Authors:  Federica Sala; Juan F Aranda; Noemi Rotllan; Cristina M Ramírez; Binod Aryal; Leonardo Elia; Gianluigi Condorelli; Alberico Luigi Catapano; Carlos Fernández-Hernando; Giuseppe Danilo Norata
Journal:  Thromb Haemost       Date:  2014-07-10       Impact factor: 5.249

2.  Brain-Derived Neurotrophic Factor Expression and Signaling in Different Perivascular Adipose Tissue Depots of Patients With Coronary Artery Disease.

Authors:  Sarah Zierold; Katja Buschmann; Sogol Gachkar; Magdalena L Bochenek; David Velmeden; Lukas Hobohm; Christian-Friedrich Vahl; Katrin Schäfer
Journal:  J Am Heart Assoc       Date:  2021-03-05       Impact factor: 5.501

3.  Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment.

Authors:  Stefano Garetto; Anna Elisa Trovato; Ana Lleo; Federica Sala; Elisa Martini; Alexander G Betz; Giuseppe D Norata; Pietro Invernizzi; Marinos Kallikourdis
Journal:  Immunobiology       Date:  2015-02-26       Impact factor: 3.144

Review 4.  Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases.

Authors:  Fabrizia Bonacina; Andrea Baragetti; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Mediators Inflamm       Date:  2013-04-07       Impact factor: 4.711

5.  Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation.

Authors:  F Bonacina; S S Barbieri; L Cutuli; P Amadio; A Doni; M Sironi; S Tartari; A Mantovani; B Bottazzi; C Garlanda; E Tremoli; A L Catapano; G D Norata
Journal:  Biochim Biophys Acta       Date:  2016-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.